earnings
confidence high
sentiment positive
materiality 0.85
ANI Pharma Q2 record revenues $138M (+18% YoY); raises FY guidance
ANI PHARMACEUTICALS INC
2024-Q2 EPS reported
$0.70
revenue$275,470,000
- Record Q2 net revenues $138.0M (+18.4% YoY); Rare Disease Cortrophin Gel $49.2M (+102.4% YoY).
- GAAP net loss $(2.7)M ($(0.14)/share); adjusted non-GAAP diluted EPS $1.02; adjusted EBITDA $33.2M.
- Raised FY 2024 guidance: rev $540M-$560M, adj. EBITDA $140M-$150M, adj. EPS $4.38-$4.82.
- On track to acquire Alimera Sciences (~$5.50/sh cash + CVR) in Q3 2024, adding ILUVIEN and YUTIQ.